Skip to main content

Characterization of Phenytoin, Carbamazepine, Vinpocetine and Clorgyline Simultaneous Effects on Sodium Channels and Catecholamine Metabolism in Rat Striatal Nerve Endings

Neurochemical Research volume 34, pages 470–479 (2009)Cite this article

Abstract

The effects of two classic antiepileptic drugs (carbamazepine and phenytoin), a potential antiepileptic (vinpocetine) and a monoamine-oxidase inhibitor (clorgyline) on the simultaneous changes (detected by HPLC) on Glu, Asp, dopamine and DOPAC inside and outside striatal isolated nerve endings were investigated. Under resting conditions phenytoin, carbamazepine and clorgyline increased dopamine release. Phenytoin and clorgyline increased internal dopamine and decreased DOPAC formation. Carbamazepine decreased internal dopamine and practically did not change DOPAC formation. Glu and Asp release was unchanged. Neurotransmitter release induced by the Na+ channel opener veratridine was reduced by all the antiepileptic drugs tested, except phenytoin which, like clorgyline, facilitated veratridine-induced dopamine release. We conclude that besides the antagonism exerted by carbamazepine, phenytoin and vinpocetine on excitatory neurotransmitters release triggered by Na+ channel activation, that might importantly contribute to their anticonvulsant action, they exert different actions on striatal dopamine distribution, that might explain their different side effect profiles.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Macdonald RL, McLean MJ (1986) Anticonvulsant drugs: mechanisms of action. Adv Neurol 44:713–736

    PubMed  CAS  Google Scholar 

  2. Sitges M, Peña F, Chiu LM et al (1998) Study on the possible involvement of protein kinases in the modulation of brain presynaptic sodium channels; comparison with calcium channels. Neurochem Int 32:177–190. doi:10.1016/S0197-0186(97)00065-X

    PubMed  Article  CAS  Google Scholar 

  3. Sitges M (1989) Effect of organic and inorganic calcium channel blockers on s-amino-n-butyric acid release induced by monensin and veratrine in the absence of external calcium. J Neurochem 53:436–441. doi:10.1111/j.1471-4159.1989.tb07353.x

    PubMed  Article  CAS  Google Scholar 

  4. Sitges M, Chiu LM (1995) w-Aga IVA selectively inhibits the calcium dependent fraction of the evoked release of [3H]GABA from synaptosomes. Neurochem Res 20:1065–1071. doi:10.1007/BF00995561

    PubMed  Article  CAS  Google Scholar 

  5. Sitges M, Galindo C (2005) Omega-agatoxin-TK is a useful tool to study P-type Ca2+ channel-mediated changes in internal Ca2+ and glutamate release in depolarised brain nerve terminals. Neurochem Int 46:53–60. doi:10.1016/j.neuint.2004.07.004

    PubMed  Article  CAS  Google Scholar 

  6. Sitges M, Chiu LM, Nekrassov V (2006) Single and combined effects of carbamazepine and vinpocetine on depolarization-induced changes in Na(+), Ca(2+) and glutamate release in hippocampal isolated nerve endings. Neurochem Int 49:55–61. doi:10.1016/j.neuint.2005.12.019

    PubMed  Article  CAS  Google Scholar 

  7. Sitges M, Chiu LM, Nekrassov V (2007) Effects of carbamazepine, phenytoin, lamotrigine, oxcarbazepine, topiramate and vinpocetine on Na+ channel-mediated release of [3H]glutamate in hippocampal nerve endings. Neuropharmacology 52:598–605. doi:10.1016/j.neuropharm.2006.09.002

    PubMed  Article  CAS  Google Scholar 

  8. Nekrassov V, Sitges M (2006) Additive effects of antiepileptic drugs and pentylenetetrazole on hearing. Neurosci Lett 406:276–280. doi:10.1016/j.neulet.2006.07.042

    PubMed  Article  CAS  Google Scholar 

  9. Hindmarch I, Fuchs HH, Erzigkeit H (1991) Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol 6:31–34. doi:10.1097/00004850-199100610-00005

    PubMed  Article  CAS  Google Scholar 

  10. Caksen H, Odabas D, Anlar O (2003) Use of biperiden hydrochloride in a child with severe dyskinesia induced by phenytoin. J Child Neurol 18:494–496. doi:10.1177/08830738030180070101

    PubMed  Article  Google Scholar 

  11. Girija A (2002) Paroxysmal dyskinesia in phenytoin toxicity. J Assoc Physicians India 50:1449–1450

    PubMed  CAS  Google Scholar 

  12. Montenegro M, Scotoni A, Cendes F (1999) Dyskinesia induced by phenytoin. Arq Neuropsiquiatr 57:356–360

    PubMed  CAS  Google Scholar 

  13. Chaudhary N, Ravat S, Shah P (1998) Phenytoin induced dyskinesia. Indian Pediatr 35:274–276

    PubMed  CAS  Google Scholar 

  14. Sethi K, Hitri A, Diamond B (1990) Phenytoin potentiation of neuroleptic-induced dyskinesias. Mov Disord 5:325–327. doi:10.1002/mds.870050413

    PubMed  Article  CAS  Google Scholar 

  15. Dravet C, Dalla Bernardina B, Mesdjian E et al (1980) Paroxysmal dyskinesia during treatment with diphenylhydantoin. Rev Neurol (Paris) 136:1–14

    CAS  Google Scholar 

  16. Nausieda P, Koller W, Weiner W et al (1979) Clinical and experimental studies of phenytoin-induced hyperkinesias. J Neural Transm 45:291–305. doi:10.1007/BF01247146

    PubMed  Article  CAS  Google Scholar 

  17. Jacome D (1979) Carbamazepine-induced dystonia. JAMA 241:2263. doi:10.1001/jama.241.21.2263b

    PubMed  Article  CAS  Google Scholar 

  18. Schwartzman M, Leppik I (1990) Carbamazepine-induced dyskinesia and ophthalmoplegia. Cleve Clin J Med 57:367–372

    PubMed  CAS  Google Scholar 

  19. Yao H, Sadoshima S, Ishitsuka T et al (1988) Massive striatal dopamine release in acute cerebral ischemia in rats. Experientia 44:506–508. doi:10.1007/BF01958929

    PubMed  Article  CAS  Google Scholar 

  20. Kawano T, Tsutsumi K, Miyake H et al (1988) Striatal dopamine in acute cerebral ischemia of stroke-resistant rats. Stroke 19:1540–1543

    PubMed  CAS  Google Scholar 

  21. Slivka A, Brannan T, Weinberger J et al (1988) Increase in extracellular dopamine in the striatum during cerebral ischemia: a study utilizing cerebral microdialysis. J Neurochem 50:1714–1718. doi:10.1111/j.1471-4159.1988.tb02468.x

    PubMed  Article  CAS  Google Scholar 

  22. Hillered L, Hallström A, Segersvärd S et al (1989) Dynamics of extracellular metabolites in the striatum after middle cerebral artery occlusion in the rat monitored by intracerebral microdialysis. J Cereb Blood Flow Metab 9:607–616

    PubMed  CAS  Google Scholar 

  23. Toner CC, Stamford JA (1999) Effects of metabolic alterations on dopamine release in an in vitro model of neostriatal ischaemia. Brain Res Bull 48:395–399. doi:10.1016/S0361-9230(99)00016-7

    PubMed  Article  CAS  Google Scholar 

  24. Freitas R, Oliveira Ade A, Vasconcelos SM et al (2006) Expression of muscarinic and dopaminergic receptors and monoamine levels frontal cortex of epileptic rats. Pharmacol Biochem Behav 83:302–306. doi:10.1016/j.pbb.2006.02.011

    PubMed  Article  CAS  Google Scholar 

  25. Balestreri R, Fontana L, Astengo F (1987) A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J Am Geriatr Soc 35:425–430

    PubMed  CAS  Google Scholar 

  26. King GA (1987) Protective effects of vinpocetine and structurally related drugs on the lethal consequences of hypoxia in mice. Arch Int Pharmacodyn Ther 286:299–307

    PubMed  CAS  Google Scholar 

  27. Sauer D, Rischke R, Beck T et al (1988) Vinpocetine prevents ischemic cell damage in rat hippocampus. Life Sci 43:1733–1739. doi:10.1016/0024-3205(88)90485-7

    PubMed  Article  CAS  Google Scholar 

  28. Rischke R, Krieglstein J (1990) Effects of vinpocetine on local cerebral blood flow and glucose utilization seven days after forebrain ischemia in the rat. Pharmacology 41:153–160. doi:10.1159/000138712

    PubMed  Article  CAS  Google Scholar 

  29. Araki T, Kogure K, Nishioka K (1990) Comparative neuroprotective effects of pentobarbital, vinpocetine, flunarizine and ifenprodil on ischemic neuronal damage in the gerbil hippocampus. Res Exp Med (Berl) 190:19–23

    CAS  Google Scholar 

  30. Trejo F, Nekrassov V, Sitges M (2001) Characterization of vinpocetine effects on DA and DOPAC release in striatal isolated nerve endings. Brain Res 909:59–67. doi:10.1016/S0006-8993(01)02621-X

    PubMed  Article  CAS  Google Scholar 

  31. Willow M, Kuenzel EA, Catterall WA (1984) Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol Pharmacol 25:228–234

    PubMed  CAS  Google Scholar 

  32. Deffois A, Fage D, Carter C (1996) Inhibition of synaptosomal veratridine-induced sodium influx by antidepressants and neuroleptics used in chronic pain. Neurosci Lett 220:117–120. doi:10.1016/S0304-3940(96)13227-4

    PubMed  Article  CAS  Google Scholar 

  33. Bonifacio MJ, Sheridan RD, Parada A et al (2001) Interaction of the novel anticonvulsant, BIA 2–093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia 42:600–608. doi:10.1046/j.1528-1157.2001.43600.x

    PubMed  Article  CAS  Google Scholar 

  34. Santangeli S, Sills GJ, Thompson GG et al (2002) Na+ channel effects of remacemide and desglycinyl-remacemide in rat cortical synaptosomes. Eur J Pharmacol 438:63–68. doi:10.1016/S0014-2999(02)01297-9

    PubMed  Article  CAS  Google Scholar 

  35. Lingamaneni R, Hemmings HCJ (2003) Differential interaction of anaesthetics and antiepileptic drugs with neuronal Na+ channels, Ca2+ channels, and GABA(A) receptors. Br J Anaesth 90:199–211. doi:10.1093/bja/aeg040

    PubMed  Article  CAS  Google Scholar 

  36. Tretter L, Adam-Vizi V (1998) The neuroprotective drug vinpocetine prevents veratridine-induced [Na+]i and [Ca2+]i rise in synaptosomes. NeuroReport 9:1849–1853. doi:10.1097/00001756-199806010-00034

    PubMed  Article  CAS  Google Scholar 

  37. Sitges M, Nekrassov V (1999) Vinpocetine selectively inhibits neurotransmitter release triggered by sodium channel activation. Neurochem Res 24:1585–1591. doi:10.1023/A:1021164418478

    PubMed  Article  CAS  Google Scholar 

  38. Sitges M, Galvan E, Nekrassov V (2005) Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosomes. Neurochem Int 46:533–540. doi:10.1016/j.neuint.2005.02.001

    PubMed  Article  CAS  Google Scholar 

  39. Selmeczy Z, Vizi E, Csóka B et al (2008) Role of nonsynaptic communication in regulating the immune response. Neurochem Int 52:52–59. doi:10.1016/j.neuint.2007.06.001

    PubMed  Article  CAS  Google Scholar 

  40. Syková E, Vargová L (2008) Extrasynaptic transmission and the diffusion parameters of the extracellular space. Neurochem Int 52:5–13. doi:10.1016/j.neuint.2007.04.007

    PubMed  Article  Google Scholar 

  41. Ravizza T, Gagliardi B, Noé F et al (2008) Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol Dis 29:142–160. doi:10.1016/j.nbd.2007.08.012

    PubMed  Article  CAS  Google Scholar 

  42. Vezzani A, Balosso S, Ravizza T (2008) The role of cytokines in the pathophysiology of epilepsy. Brain Behav Immun 22:797–803

    PubMed  Article  CAS  Google Scholar 

  43. Shih J, Chen K, Ridd M (1999) Monoamine oxidase: from genes to behavior. Annu Rev Neurosci 22:197–217

    PubMed  Article  CAS  Google Scholar 

  44. Adachi Y, Watanabe K, Higuchi H et al (2001) Oxygen inhalation enhances striatal dopamine metabolism and monoamineoxidase enzyme inhibition prevents it: a microdialysis study. Eur J Pharmacol 422:61–68. doi:10.1016/S0014-2999(01)01074-3

    PubMed  Article  CAS  Google Scholar 

  45. Sitges M, Nekrassov V, Guarneros A (2000) Simultaneous action of MK-801 (dizclopine) on dopamine, glutamate, aspartate and GABA release from striatum isolated nerve endings. Brain Res 854:48–56. doi:10.1016/S0006-8993(99)02282-9

    PubMed  Article  CAS  Google Scholar 

  46. Langer S (2008) Presynaptic autoreceptors regulating transmitter release. Neurochem Int 52:26–30

    PubMed  Article  CAS  Google Scholar 

  47. Lajtha A (2008) Interrelated mechanisms in reward and learning. Neurochem Int 52:73–79. doi:10.1016/j.neuint.2007.08.019

    PubMed  Article  CAS  Google Scholar 

  48. Ahmad S, Fowler L, Whitton P (2005) Lamotrigine, carbamazepine and phenytoin differentially alter extracellular levels of 5-hydroxytryptamine, dopamine and amino acids. Epilepsy Res 63:141–149. doi:10.1016/j.eplepsyres.2005.02.002

    PubMed  Article  CAS  Google Scholar 

  49. Waldmeier P, Baumann P, Wicki P et al (1995) Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology 45:1907–1913

    PubMed  CAS  Google Scholar 

  50. Pauwels P, Van Assouw L, Peeters L et al (1990) Neurotoxic action of veratridine in rat brain neuronal cultures: mechanism of neuroprotection by Ca++ antagonists nonselective for slow Ca++ channels. J Pharmacol Exp Ther 255:1117–1122

    PubMed  CAS  Google Scholar 

  51. Thán M, Kocsis P, Tihany K et al (2007) Concerted action of antiepileptic and antidepressant agents to depress spinal neurotransmission: possible use in the therapy of spasticity and chronic pain. Neurochem Int 50:642–652. doi:10.1016/j.neuint.2006.12.008

    PubMed  Article  Google Scholar 

  52. Orio L, O’Shea E, Pradillo J et al (2004) 3,4-Methylenedioxymethamphetamine increases interleukin-1beta levels and activates microglia in rat brain: studies on the relationship with acute hyperthermia and 5-HT depletion. J Neurochem 89:1445–1453. doi:10.1111/j.1471-4159.2004.02443.x

    PubMed  Article  CAS  Google Scholar 

  53. Zhang L, Shirayama Y, Shimizu E et al (2006) Protective effects of minocycline on 3,4-methylenedioxymethamphetamine-induced neurotoxicity in serotonergic and dopaminergic neurons of mouse brain. Eur J Pharmacol 544:1–9. doi:10.1016/j.ejphar.2006.05.047

    PubMed  Article  CAS  Google Scholar 

  54. Lazarus A (1994) Tardive dyskinesia-like syndrome associated with lithium and carbamazepine. J Clin Psychopharmacol 14:146–147. doi:10.1097/00004714-199404000-00012

    PubMed  Article  CAS  Google Scholar 

  55. Chua H, Venketasubramanian N, Tan C et al (1999) Paradoxical seizures in phenytoin toxicity. Singapore Med J 40:276–277

    PubMed  CAS  Google Scholar 

  56. Clifford D, Olney J, Benz A et al (1994) Ketamine, phencyclidine, and MK-801 protect against kainic acid-induced seizure-related brain damage. Epilepsia 31:382–390. doi:10.1111/j.1528-1157.1990.tb05492.x

    Article  Google Scholar 

  57. Peterson S (1995) Infusion of NMDA antagonists into the nucleus reticularis pontis oralis inhibits the maximal electroshock seizure response. Brain Res 702:101–109. doi:10.1016/0006-8993(95)01026-2

    PubMed  Article  CAS  Google Scholar 

  58. Carter A (1994) Many agents that antagonize the NMDA receptor-channel complex in vivo also cause disturbances of motor coordination. J Pharmacol Exp Ther 269:573–580

    PubMed  CAS  Google Scholar 

  59. Sitges M, Guarneros A, Nekrassov V (2007) Effects of carbamazepine, phenytoin, valproic acid, oxcarbazepine, lamotrigine, topiramate and vinpocetine on the presynaptic Ca2+ channel-mediated release of [3H]glutamate: comparison with the Na+ channel-mediated release. Neuropharmacology 53:854–862. doi:10.1016/j.neuropharm.2007.08.016

    PubMed  Article  CAS  Google Scholar 

  60. Nekrassov V, Sitges M (2004) Vinpocetine inhibits the epileptic cortical activity and auditory alterations induced by pentylenetetrazole in the guinea pig in vivo. Epilepsy Res 60:63–71. doi:10.1016/j.eplepsyres.2004.05.005

    PubMed  Article  CAS  Google Scholar 

  61. Sitges M, Nekrassov V (2004) Vinpocetine prevents 4-aminopyridine-induced changes in the EEG, the auditory brainstem responses and hearing. Clin Neurophysiol 115:2711–2717. doi:10.1016/j.clinph.2004.06.019

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank Araceli Guarneros for her excellent technical assistance. This work was partially supported by grants 225008 from PAPIIT and D-48695 from SEP-CONACYT. Blanca I. Aldana García scholarship was also supported by grant 225008 from PAPIIT.

Author information

Affiliations

  1. Depto. de Biología Celular y Fisiología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Apartado Postal 70228, Ciudad Universitaria, 04510, Mexico, D.F., Mexico

    María Sitges, Blanca I. Aldana & Luz M. Chiu

  2. División de Investigación Básica y Aplicada, Instituto Nacional de Rehabilitación, SSA, Mexico, D.F., Mexico

    Vladimir Nekrassov

Authors
  1. María Sitges
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Blanca I. Aldana
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luz M. Chiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vladimir Nekrassov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to María Sitges.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sitges, M., Aldana, B.I., Chiu, L.M. et al. Characterization of Phenytoin, Carbamazepine, Vinpocetine and Clorgyline Simultaneous Effects on Sodium Channels and Catecholamine Metabolism in Rat Striatal Nerve Endings. Neurochem Res 34, 470–479 (2009). https://doi.org/10.1007/s11064-008-9805-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11064-008-9805-7

Keywords

  • Antiepileptic drugs
  • Monoamino-oxidase
  • Dopamine
  • DOPAC
  • Glutamate
  • Aspartate
  • Veratridine